IP Library Granted Patent US 12,509,448
Granted Patent B2
US 12,509,448 · App. 17/779,476 · Granted Dec 30, 2025

Salts of indoleamine 2,3-dioxygenase inhibitors

Inventors: Xing Dai (Shanghai, CN); Yueheng Jiang (Shanghai, CN); Yanqin Liu (Shanghai, CN)
Assignee: INVENTISBIO CO., LTD.
C07D405/12A61K31/4433A61K45/06A61P31/10A61P35/00C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,509,448
App. No.
17/779,476
Granted
Dec 30, 2025
Kind
B2
Abstract

Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to IDO inhibitors, in particular, Compound 1,1-(5-((4-chlorophenyl)amino)-6-(ethyl(tetrahydro-2H-pyran-4-yl)amino)pyridin-3-yl)cyclobutane-1-carboxylic acid. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof one or more of the compounds or compositions of the present disclosure.

Claims (13)

1 . A hydrochloride salt of Compound 1:

which is in a crystalline Form I, characterized by an X-ray powder diffraction (XRPD) pattern having the following peaks: 14.7, 17.5, 19.8, 22.4, 22.9 degrees 2 theta, ±0.2°.

2 . The hydrochloride salt of claim 1 , wherein the crystalline Form I is characterized by an X-ray powder diffraction (XRPD) pattern having the following peaks: 12.7, 14.7, 15.0, 15.9, 17.5, 18.7, 19.8, 20.5, 22.4, 22.9, 24.8, 25.5, 26.2, 28.4, 28.7, 29.0 and 30.1 degrees 2 theta, ±0.2°.

3 . The hydrochloride salt of claim 1 , which is prepared by a process comprising: a) mixing Compound 1 and HCl in a solvent system comprising at least one non-aqueous solvent to form the hydrochloride salt; and b) separating the hydrochloride salt from the solvent system.

4 . The hydrochloride salt of claim 3 , wherein the at least one non-aqueous solvent comprises isopropanol.

5 . The hydrochloride salt of claim 3 , wherein the solvent system is free of a primary alcohol.

6 . The hydrochloride salt of claim 1 , which has a purity by weight and/or by HPLC area of at least 90%.

7 . A pharmaceutical composition comprising the hydrochloride salt of claim 1 , and optionally a pharmaceutically acceptable excipient.

8 . The pharmaceutical composition of claim 7 , which is free of Compound 1 in free acid form.

9 . The pharmaceutical composition of claim 7 , comprising the hydrochloride salt, wherein the pharmaceutical composition is free of Compound 1 in a salt form other than hydrochloride salt.

10 . The pharmaceutical composition of claim 7 , comprising the hydrochloride salt, wherein the pharmaceutical composition is free of hydrochloride salt of Compound 1 in a solid form other than Form I.

11 . The pharmaceutical composition of claim 7 , further comprising hydrochloride salt of Compound 1 in an amorphous form.

12 . The pharmaceutical composition of claim 7 , which is a solid dosage form.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2022
From: DAI, XING; JIANG, YUEHENG; LIU, YANQIN
To: INVENTISBIO CO., LTD.
Reel/Frame 061078/0697 →
Priority Claims (1)
WO PCT/CN2019/120531 · Nov 25, 2019 · international
Continuity (1)
Related Publication 20230027952A1 · Jan 26, 2023
References Cited (19)
US 9790169B2 · Balog et al. · 2017 [cited by applicant]
US 10167254B2 · Balog et al. · 2019 [cited by applicant]
US 10399932B2 · Balog et al. · 2019 [cited by applicant]
US 10399933B2 · Balog et al. · 2019 [cited by applicant]
US 10980807B2 · Dai · 2021 [cited by examiner]
US 20160289171A1 · Balog et al. · 2016 [cited by applicant]
US 20170231999A1 · Balog et al. · 2017 [cited by applicant]
US 20180072660A1 · Balog et al. · 2018 [cited by applicant]
US 20180079712A1 · Balog et al. · 2018 [cited by applicant]
CN 105324362 · 2016 [cited by applicant]
CN 108260355 · 2018 [cited by applicant]
CN 109071423 · 2018 [cited by applicant]
WO 2014150646 · 2014 [cited by applicant]
WO 2017051353 · 2017 [cited by applicant]
Bastin, Richard J., Michael J. Bowker, and Bryan J. Slater. “Salt selection and optimisation procedures for pharmaceutical new chemical entities.” Organic Process Research & Development 4, No. 5 (2000): 427-435) (Year: … [cited by examiner]
International Search Report for PCT/CN2019/120531 dated Jul. 29, 2020, 4 pages. [cited by applicant]
Written Opinion of the ISA for PCT/CN2019/120531 dated Jul. 29, 2020, 7 pages. [cited by applicant]
International Search Report for PCT/CN2020/130734 dated Mar. 3, 2021, 6 pages. [cited by applicant]
Written Opinion of the ISA for PCT/CN2020/130734 dated Mar. 3, 2021, 6 pages. [cited by applicant]